TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07201688: Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Recombinant Human TNK Tissue-Type Plasminogen Activator for Injection (rhTNK-tPA, Mingfule) in Intravenous Thrombolysis for Acute Isch

Sponsor: CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 890 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$17,630,720

Rescue Site Savings

+$11,625,256

Unlock Full NCT07201688 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07201688 Rescue Dossier →